FDA Panel: Heart Closure Device Safety Data Demands Further Study
This article was originally published in The Gray Sheet
Executive Summary
More study is required to make sense of the adverse event rates associated with two marketed atrial septal defect occluders, a May 24 FDA panel concluded. St. Jude Medical, in particular, should start a new prospective study for its Amplatzer device, the panel recommends.
You may also be interested in...
Case Closed On PFO Closure? A Principal Investigator Weighs In
Future prospects for devices that close patent foramen ovale heart defects to prevent recurrent strokes remain in some doubt as researchers continue to mull recent data.
AGA Purchase Gives St. Jude Structural Heart Leadership, Growth Potential
St. Jude Medical will become the market leader in structural heart defect closure devices with its planned $1.3 billion purchase of AGA Medical.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”